RxDoctor Payments Data

Garrett Soileau, PA

Physician Assistant · Ruston, LANPI 1992465488

Payments from drug & device makers

$4,186in general payments, 2019–2025

Across 231 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Sanofi$828
  • Johnson & Johnson$480
  • Novartis$377
  • Pfizer$337
  • LEO Pharma Inc.$232
  • plus $749 from 15 others

What the payments were for

  • Food & beverage$3,86792%
  • Education$3208%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,186 in reported general payments places this provider in the 90th percentile of 1,246 physician assistant providers in Louisiana.

See all physician assistant providers in Louisiana

Medicare billing

Part B allowed, 2024
$52,579
Medicare patients
361
Services billed
807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab175$686,095
RinvoqUpadacitinib40$274,818
XolairOmalizumab29$79,099
OtezlaApremilast11$58,425
OpzeluraRuxolitinib Phosphate23$46,904
Fluorouracil123$8,733
Tacrolimus59$6,510
Betamethasone Dipropionate105$5,445
Metronidazole35$4,277
Ketoconazole216$3,942
Betamethasone Valerate130$3,741
Triamcinolone Acetonide308$3,369
Doxycycline Hyclate145$2,456
Clobetasol Propionate93$2,386
Clindamycin Phosphate48$1,998

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,184$274,81840 claims
AmgenOtezla$35$58,42511 claims
Incyte CorporationOpzelura$149$46,90423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 physician assistant providers in Louisiana.

Other physician assistant in Ruston

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →